SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Edmund P. Harrigan, M.D., has joined its Board of Directors. Dr. Harrigan is a board-certified neurologist with 25 years of executive leadership experience in the pharmaceutical industry, most recently serving as Senior Vice President, Worldwide Safety and Regulatory at Pfizer Inc.
